At Paragon Genomics, we develop and commercialize rapid, easy-to-use, and ultra-high multiplex PCR-based target enrichment solutions for the Next-Generation Sequencing (NGS) markets. Our proprietary CleanPlex background-removing technology enables NGS customers to develop targeted sequencing assays that are accurate, sensitive, simple, and cost effective. Our technology is applicable to many fast-growing NGS segments such as cancer research, liquid biopsy, biomarker discovery, genomics-guided breeding, companion diagnostics, and immunotherapy monitoring.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/12/17 | $8,000,000 | Series A |
Cloudstone Venture Cowin Venture Capital  Fosun Industrial Co. HEDA Ventures Wisemont Capital | undisclosed |
